> ## Content Index > Fetch the complete content index at: https://nexi.fund/llms.txt > Use this file to discover other available public pages before exploring further. # Korea's first homegrown GLP-1 won approval. Hanmi's stock fell 6%. - URL: https://nexi.fund/hanmi-eppe-glp1-approval-2026/ - Published: 2026-10-13T10:00:22.000Z - Updated: 2026-10-13T10:00:22.000Z - Description: South Korea approved Eppe, the first GLP-1 obesity drug developed in the country. Two outlets report two different weight-loss figures for the same 448-patient trial, the week-64 result was never published, and the price is still unannounced. Hanmi's shares opened 6 percent lower the next morning. - Author: Nexi.fund Labs - Tags: Biotech & Health, #mode-1, #hook-number, #track-A, #layout-thesis-spine ₩502,000 was Hanmi Pharmaceutical's opening price on the Thursday after South Korea's drug regulator approved Eppe. Six percent below the previous close. The country's first homegrown GLP-1 obesity drug had cleared review the night before. Efpeglenatide is not a new molecule. Hanmi discovered it, licensed it to Sanofi in 2015, and got it back in 2020\. Eleven years of development, and the approval took minutes. What is new sits in a single number. Almost all Korean GLP-1 spending goes to imports. Hanmi's own trial result lands below both of those imported products. 🎯 **Three things the approval settles, and one it does not.** Korea can now make a GLP-1 from active ingredient to finished auto-injector on its own soil, ending the import dependency that has shaped roughly 2 trillion won of annual domestic spending. Tolerability is the strongest part of the package. Diarrhea appeared in 17.6 percent of trial patients and nausea in 16.6 percent, figures Korea JoongAng Daily puts below Wegovy. Reusable clinical ground exists. A cardiovascular outcomes trial run with the former global partner covered about 6,000 diabetes patients, and a second phase 3 in type 2 diabetes began dosing in April 2026. What the approval does not settle is whether a drug averaging about 9 percent weight loss holds Korean prescriptions once the starting price is announced, against 14.9 percent reported for semaglutide and up to 20.9 percent for tirzepatide. ## What actually got approved The Ministry of Food and Drug Safety cleared Eppe Auto Injector on 7 October 2026\. Five strengths: 2, 4, 6, 8 and 10 milligrams. Active ingredient efpeglenatide, code HM11260C. It is Korea's 45th homegrown novel drug. The label is narrower than the usual launch language. Eppe covers chronic weight management, taken with diet and exercise. Patients need a body mass index of 30 or above, or 27 and above with one weight-related condition. Diabetes is excluded. That exclusion matters. The cardiovascular dataset Hanmi leans on comes from diabetes patients. Dosing climbs 2, 4, 6 and 8 mg across twelve weeks. Maintenance sits at 10 mg once a week. Hanmi handled discovery and manufacturing in house. The Pyeongtaek plant south of Seoul will make the active ingredient and the finished dose. ## Two numbers for one trial Four hundred and forty-eight Korean adults with obesity entered the final phase 3\. Average age 43\. Average weight 89 kilograms. Average body mass index 32. Two outlets covering the same approval report two different weight-loss figures for the same trial at the same 40-week mark. Korea JoongAng Daily put average loss at 9.02 percent on 8 October. Placebo managed 0.89 percent. Seventy-five point one percent of patients dropped at least 5 percent of body weight. Placebo reached 13.5 percent. Aju Press and Korea Biomedical Review report 9.75 percent instead. Both trace it to Hanmi's interim topline from October 2025. Korea Biomedical Review adds the breakdown. 79.42 percent lost at least 5 percent. 49.46 percent lost 10 percent or more. 19.86 percent reached 15 percent. One patient lost 30. No source in this coverage explains the gap. The full trial ran 64 weeks. Hanmi has not published the week-64 average. | Measure | Eppe (efpeglenatide) | Imported comparators, as reported | | ----------------------------------- | ----------------------------------------------------------------------------- | ------------------------------------------------------------------------------ | | **Average weight loss** | 9.02% at 40 weeks vs 0.89% placebo; 9.75% in the October 2025 interim topline | 14.9% for semaglutide over 68 weeks; up to 20.9% for tirzepatide over 72 weeks | | **Lost at least 5% of body weight** | 75.1% reported; 79.42% on the interim figure | Not stated in the sources used here | | **Average baseline BMI** | about 32 | about 38, per the Korean trial's principal investigator | | **Head-to-head evidence** | None. Eppe has never been tested against Wegovy or Mounjaro | — | Sources: Korea JoongAng Daily and Korea Biomedical Review, 8 October 2026; Aju Press, 8 October 2026\. Cross-trial comparison only. That last row is the honest version of the efficacy case. No head-to-head trial exists. Every percentage comparison runs through at least three uncontrolled variables. Professor Kim Sung-rae led the Korean efpeglenatide trial. He sits at Catholic University of Korea, Bucheon St. Mary's Hospital. He made the defence himself on a medical programme. Imported trials generally enrolled patients averaging a body mass index near 38\. The Korean study averaged 32\. It also ran 40 weeks, against 68 for semaglutide and 72 for tirzepatide. He calls weight loss around 10 percent clinically meaningful for Korean patients. That defence is sound. It is also incomplete. A lower baseline index leaves less fat to lose, which flatters the headline. A 40-week readout flatters the curve. Both effects favour Eppe in a comparison Hanmi is already making. ## The tolerability case, and its limit Gastrointestinal events in the Korean trial ran as follows. Diarrhea affected 17.6 percent of patients. Nausea followed at 16.6 percent. Indigestion came to 15.6 percent, constipation to 14.6 percent, and vomiting to 11.6 percent. Korea JoongAng Daily reads those figures as below Wegovy, and at or below Mounjaro. Hanmi's explanation is unglamorous. The company credits LAPSCOVERY, its long-acting peptide platform. Combined with stepwise escalation, it is meant to flatten exposure peaks during titration. > We are preparing to supply the product to the market as early as the end of this month. The price has not yet been finalized, but we plan to set it at a level that can ease the burden on patients who require long-term treatment and lower the barrier to accessing obesity drugs.— Hanmi Pharmaceutical spokesperson The limit is simple. Without a comparative trial, better tolerability is an inference from cross-trial tables. That is the reasoning behind a long list of obesity drugs approved on thinner evidence. Hanmi concedes the point in its own coverage. Direct comparative evidence would be needed. The cardiovascular claim needs the same treatment. AMPLITUDE-O ran with the former global partner across roughly 6,000 patients with type 2 diabetes. Major adverse cardiovascular events fell 27 percent in relative terms. Kidney disease progression fell by more than 30 percent. Strong results, in the population where they were measured. Korea Biomedical Review states plainly that they do not carry over to an obesity label. ## The 2 trillion won problem South Korea's GLP-1 market has reached about 2 trillion won. That is roughly 1.49 billion dollars. Most of it goes to global drugmakers, according to Hanmi. Wegovy and Mounjaro split it between them. Hanmi has published no price. The company says only that the starting dose will be competitive. That leaves the only two questions a prescriber and a payer will ask unanswered. Price and supply are where a domestic entrant has structural ground. Imported GLP-1s have run into shortages. Monthly treatment costs in the hundreds of thousands of won push patients off therapy early. Obesity treatment is chronic. Discontinuation is the market problem. Supply reliability is the one axis Hanmi controls outright. 📊 **Three numbers to watch before launch** The starting-dose price, announced at launch and not before. The reimbursement listing decision, which is what actually gates Korean uptake. The week-64 weight-loss figure from the phase 3 that Hanmi has so far withheld. Kim Na-young runs innovative growth at Hanmi. She frames the approval as industrial policy: domestic production strengthens Korean pharmaceutical self-sufficiency. The ministry counted Eppe as the country's 45th homegrown novel drug, which supports that reading. ## Eleven years to get here Efpeglenatide was discovered by Hanmi and licensed to Sanofi in 2015\. The upfront payment was 400 million euros, with up to 3.5 billion euros in milestones. It sat inside a long-acting diabetes portfolio built on LAPSCOVERY. Sanofi returned the rights in 2020\. Hanmi refocused the molecule on obesity. The Korean trials followed. The platform is still generating filings. A second phase 3 in type 2 diabetes began dosing on 13 April 2026\. It finishes in 2028, testing efpeglenatide against placebo on top of metformin and dapagliflozin. A digital lifestyle platform is in development alongside the drug. It targets adherence, and the weight regain that follows discontinuation. So the commercial question narrows to one number nobody has published. Eppe enters a market it can manufacture for, at a price it has not set, against two imported products that lose more weight and cost more to supply. Approval removed the regulatory question. It left the commercial one untouched. ### Can a home label hold share against two imports that lose more weight? 🔮 **Eppe reaches 5 percent of Korean GLP-1 prescriptions by the end of Q1 2027.** Probability: 25 percent — a starting dose below the imported equivalents plus reliable domestic supply is enough to pull switchers and new starts, and 5 percent is the share a well-executed domestic entry typically reaches in a two-importer market. #### ✅ Arguments for Gastrointestinal tolerability is the axis on which Eppe leads in cross-trial tables, and tolerability is what drives discontinuation on a therapy patients take for years. End-to-end domestic production from active ingredient to auto-injector removes the supply risk that has periodically stranded Korean patients on imported therapy. Reimbursement listing would extend access to patients who cannot sustain imported monthly costs in the hundreds of thousands of won. **Confirmation criteria:** a starting-dose price below the imported equivalents, a positive reimbursement listing inside two quarters of launch, and a week-64 weight-loss figure at or above 10 percent. #### ❌ Arguments against A 9 percent average sits below both incumbents, and prescribers write for the number they can quote to a patient. No head-to-head trial exists, so every tolerability and efficacy comparison runs through uncontrolled cross-trial tables. The cardiovascular outcomes evidence comes from diabetes patients, and the approved label excludes them. **Refutation criteria:** a starting price at or above the imported equivalents, a reimbursement listing delayed past mid-2027, or a week-64 figure below 8 percent. ### Three ways this resolves #### 🟢 Domestic entrant takes real share (30%) The starting dose lands materially below the imported price, and reimbursement listing follows within two quarters. Supply reliability becomes the deciding factor for prescribers who have watched imported therapy run short. **Consequence:** Eppe reaches 5 to 8 percent of Korean prescriptions by Q1 2027, and Hanmi's 2027 obesity revenue justifies the platform investment on its own. #### 🟡 Slow adoption (55%) The price undercuts the imports only slightly, reimbursement listing lags, and prescribers keep writing the drug with the larger published weight-loss figure. Eppe builds a durable 2 to 4 percent base among patients who abandoned imported therapy over side effects. **Consequence:** a stable niche business and a platform that carries the 2028 diabetes readout, with the obesity indication working as proof of concept rather than a growth engine. #### 🔴 Oral formulations take the volume (15%) Small-molecule oral GLP-1s continue taking share from injectables, and a domestically manufactured oral option arrives before Eppe establishes itself. The weekly injection becomes a supply story instead of a share story. **Consequence:** Eppe defends reimbursement on supply reliability and durability while volume migrates to oral formulations, leaving Hanmi with the manufacturing base and less of the market it was approved to enter. ## Sources [ Korea approves its first homegrown GLP-1 drug, with less weight loss and fewer side effects The fullest available account of the phase 3 readout: 448 patients, 9.02 percent average loss at 40 weeks against 0.89 percent on placebo, the full adverse-event table, the titration schedule and the 2015 Sanofi licensing history. Korea JoongAng Daily, 8 October 2026 ](https://www.koreajoongangdaily.com/business/koreas-first-glp1-obesity-drug-wins-approval-with-less-weight-loss-but-fewer-side-effects/12910491?ref=nexi.fund) The primary numeric source. It is also the only outlet in this set that reports a placebo comparator, which is why the 9.02 percent figure sits next to the 9.75 percent one throughout. [ Hanmi's Eppe becomes Korea's first homegrown GLP-1 obesity drug Where the market arithmetic comes from: a domestic GLP-1 market of about 2 trillion won, and a share price that opened 6 percent lower at 502,000 won the morning after the approval. Aju Press, 8 October 2026 ](https://www.ajupress.com/view/20261008081905353?ref=nexi.fund) The clearest signal that the approval itself was not the news investors were waiting for. [ Hanmi's Eppe enters the Korean obesity drug race with local trial data and open pricing questions Sector-level analysis: the responder breakdown from Hanmi's interim topline, the principal investigator's baseline-BMI defence, and the AMPLITUDE-O cardiovascular and kidney results from about 6,000 diabetes patients. Korea Biomedical Review, 8 October 2026 ](https://www.koreabiomed.com/news/articleView.html?idxno=33438&ref=nexi.fund) Also the source that states the limit on the cardiovascular claim in plain terms: those outcomes were measured in diabetes patients and do not carry over to an obesity label. [ Sanofi and Hanmi announce licence agreement to develop long-acting diabetes treatments The origin of the molecule, eleven years before approval: 400 million euros upfront, up to 3.5 billion euros in milestones, and the LAPSCOVERY platform that the returned-rights programme was rebuilt on. Fierce Biotech, 5 November 2015 ](https://www.fiercebiotech.com/biotech/sanofi-and-hanmi-announce-license-agreement-to-develop-portfolio-of-long-acting-diabetes?ref=nexi.fund) Background rather than event coverage. It belongs here because the 2015 out-licensing and the 2020 return are the reason this reads as a domestic approval story at all.